Wells Fargo Maintains Overweight on Beam Therapeutics, Lowers Price Target to $70
Preview: Natera's Earnings
Here Are the Major Earnings After the Close Today
10 Analysts Assess Beam Therapeutics: What You Need To Know
Tempus AI Analyst Ratings
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $25
Beam Therapeutics Analyst Ratings
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
Natera's Prospera Heart With DQS Cuts False Positives By Over 37%, Outperforming Dd-cfDNA Percentage Alone, AJT Publication Shows
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $82
CRISPR Therapeutics Analyst Ratings
Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressures
Earnings Call Summary | Tempus AI(TEM.US) Q1 2025 Earnings Conference
Tempus AI Q1 Earnings: Revenue Beat, EPS Beat, Raised FY Guidance, Shares Surge
Schrödinger Q1 2025 Earnings Preview
CRISPR Therapeutics Q1 EPS $(1.58) Misses $(1.21) Estimate, Sales $865.00K Miss $6.50M Estimate
Tempus AI Q1 Adj. EPS $(0.24) Beats $(0.27) Estimate, Sales $255.74M Beat $248.13M Estimate
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $60
Guggenheim Reiterates Buy on Twist Bioscience, Maintains $50 Price Target